Ajjai S Alva
Clinical Professor
[email protected]

Available to mentor
Ajjai S Alva
Clinical Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • Manage Your Profile
    About

    Maisel Research Professor of Clinical and Translational Oncology
    Clinical Professor, Division of Hematology Oncology, Department of Internal Medicine
    Steering Committee Member, ORP NCCN
    University of Michigan Rogel Comprehensive Cancer Center
    Physician Co-Lead, GU Oncology Disease Group
    Hematology-Oncology Peer Review Committee GU Member
    Hematology-Oncology Coordination Committee Member

    Qualifications
    • MS Cell Biology Molecular Genetics
      University of Maryland, College Park, 2004
    • MB BS
      Jawaharlal Institute of Postgraduate Medical Education and Research, 2000
    • FASCO
      American Society of Clinical Oncology
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    GU oncology Therapeutics
    Biomarkers including ctDNA, Genomics
    Radiomics in Immunotherapy
    Clinical Trials
    Mentoring Trainees in Clinical Research

    Recent Publications See All Publications
    • Journal Article
      Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data
      Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. European urology oncology, 2025 Apr 1; 8 (2): 258 - 262. DOI:10.1016/j.euo.2024.12.006
      PMID: 39709257
    • Journal Article
      Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
      Zarba M, O'Sullivan D, El Hajj Chehade R, McKay RR, Pal SK, Beuselinck B, Donskov F, Lalani A-KA, Crumbaker M, Li H, Alva AS, Powles T, Takemura K, Kollmannsberger CK, Wong SS, Wood LA, de Velasco G, Cheung WY, Choueiri TK, Heng DYC. Journal of Clinical Oncology, 2025 Feb 20; 43 (5_suppl): 479 - 479. DOI:10.1200/jco.2025.43.5_suppl.479
    • Proceeding / Abstract / Poster
      Carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE): Clinical implications of recurrent genomic alterations in lethal prostate cancer.
      Rebernick R, Hammer L, McFarlane M, Westbrook TC, Hazime M, Hammoud T, Chiu P-E, Owens X, Wu Y-M, Robinson DR, Spratt D, Alva AS, Jackson WC, Reichert ZR, Alumkal JJ, Chinnaiyan A, Cieslik M, Dess RT. Journal of Clinical Oncology, 2025 Feb 20; 43 (5_suppl): 220 - 220. DOI:10.1200/jco.2025.43.5_suppl.220
    • Journal Article
      Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.
      Jindal T, Jiang CY, Alhalabi O, Sidhom F, Jang A, Bakaloudi DR, Narula I, Jaime-Casas S, Glover M, Nizam A, Gupta S, Bilen MA, Shah S, Tripathi A, Grivas P, Brown JR, Basu A, Campbell MT, Alva AS, Koshkin VS. Journal of Clinical Oncology, 2025 Feb 20; 43 (5_suppl): 867 - 867. DOI:10.1200/jco.2025.43.5_suppl.867
    • Journal Article
      Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
      Maj D, Zarba M, Wells C, El Hajj Chehade R, Ozay ZI, Pal SK, Beuselinck B, Liow ECH, Alva AS, Powles T, Bjarnason GA, Wood L, Kanesvaran R, de Velasco G, Lee JL, Templeton AJ, McKay RR, Suárez C, Choueiri TK, Heng DYC. Journal of Clinical Oncology, 2025 Feb 20; 43 (5_suppl): 477 - 477. DOI:10.1200/jco.2025.43.5_suppl.477
    • Journal Article
      Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study
      Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SYS, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Moreno BH, Bavle A, Özgüroğlu M. Clinical Genitourinary Cancer, 2025 Feb 1; 23 (1): DOI:10.1016/j.clgc.2024.102261
      PMID: 39642775
    • Journal Article
      Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
      Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Clinical Genitourinary Cancer, 2025 Feb 1; 23 (1): DOI:10.1016/j.clgc.2024.102284
      PMID: 39798390
    • Journal Article
      Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial
      Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T. Clinical Genitourinary Cancer, 2025 Feb 1; 23 (1): DOI:10.1016/j.clgc.2024.102248
      PMID: 39579409